Glial scar brain and spinal cord. FGF2 has also been shown to increase astrocyte proliferation "in vitro". Ciliary neurotrophic factor (CNTF) is a cytosolic protein that is not secreted. CNTF has been shown to promote the survival of neuronal cultures "in vitro", and it can also act as a differentiator and trophic factor on glial cells. Further, CNTF has been previously shown to affect the differentiation of glial precursor cells "in vitro"; however, the influence of CNTF in the "in vivo" setting has only recently been determined. Winter "et al." used CNTF over-expressing transgenic mice as well as wildtype controls that had
Human embryonic stem cells clinical trials approved trials must take place in California, scientists are hopeful that this funding will bolster future research in the field. Human embryonic stem cells clinical trials The Food and Drug Administration (FDA) approved the first clinical trial in the United States involving human embryonic stem cells on January 23, 2009. Geron Corporation, a biotechnology firm located in Menlo Park, California, originally planned to enroll ten patients suffering from spinal cord injuries to participate in the trial. The company hoped that GRNOPC1, a product derived from human embryonic stem cells, would stimulate nerve growth in patients with debilitating damage to the